By Daniella Parra
Medera Inc. and CADENCE have launched Asia’s first cardiac gene therapy trial for heart failure in Singapore, they said.
The trial uses SRD-001, an adeno-associated virus-based therapy targeting heart failure with reduced ejection fraction, they said.
“The launch of the SRD-001 trial in Singapore is a landmark moment for cardiovascular cell and gene therapy research in Asia. It underscores our commitment to integrate cutting-edge research and technologies to combat cardiovascular diseases,” said Derek Hausenloy, MBBS/PhD, Executive Director of CADENCE. “By bringing together the best of our national research capabilities and expertise, we aim to pave the way for innovative treatments that can significantly improve patient outcomes.”
Editor@Executives-edge.com
